company background image
NTLA

Intellia Therapeutics NasdaqGM:NTLA Stock Report

Last Price

US$45.80

Market Cap

US$3.6b

7D

-8.2%

1Y

-58.3%

Updated

01 Dec, 2022

Data

Company Financials +
NTLA fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

NTLA Stock Overview

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics.

Intellia Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Intellia Therapeutics
Historical stock prices
Current Share PriceUS$45.80
52 Week HighUS$130.33
52 Week LowUS$37.08
Beta1.83
1 Month Change-13.93%
3 Month Change-18.23%
1 Year Change-58.35%
3 Year Change165.82%
5 Year Change116.65%
Change since IPO107.24%

Recent News & Updates

Intellia Therapeutics: Top Speculative Trade In The Biotech Space

Oct 05

Recent updates

Is Intellia Therapeutics (NASDAQ:NTLA) Weighed On By Its Debt Load?

Aug 06
Is Intellia Therapeutics (NASDAQ:NTLA) Weighed On By Its Debt Load?

Need To Know: The Consensus Just Cut Its Intellia Therapeutics, Inc. (NASDAQ:NTLA) Estimates For 2022

Feb 09
Need To Know: The Consensus Just Cut Its Intellia Therapeutics, Inc. (NASDAQ:NTLA) Estimates For 2022

We Think Intellia Therapeutics (NASDAQ:NTLA) Can Afford To Drive Business Growth

Dec 31
We Think Intellia Therapeutics (NASDAQ:NTLA) Can Afford To Drive Business Growth

Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) Intrinsic Value Is Potentially 79% Above Its Share Price

Oct 11
Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) Intrinsic Value Is Potentially 79% Above Its Share Price

Here's Why We're Not At All Concerned With Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Situation

Aug 01
Here's Why We're Not At All Concerned With Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Situation

Estimating The Intrinsic Value Of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Jul 05
Estimating The Intrinsic Value Of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Companies Like Intellia Therapeutics (NASDAQ:NTLA) Can Afford To Invest In Growth

Apr 16
Companies Like Intellia Therapeutics (NASDAQ:NTLA) Can Afford To Invest In Growth

Broker Revenue Forecasts For Intellia Therapeutics, Inc. (NASDAQ:NTLA) Are Surging Higher

Mar 12
Broker Revenue Forecasts For Intellia Therapeutics, Inc. (NASDAQ:NTLA) Are Surging Higher

Introducing Intellia Therapeutics (NASDAQ:NTLA), The Stock That Soared 360% In The Last Year

Mar 03
Introducing Intellia Therapeutics (NASDAQ:NTLA), The Stock That Soared 360% In The Last Year

Are Institutions Heavily Invested In Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) Shares?

Jan 18
Are Institutions Heavily Invested In Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) Shares?

Here's Why We're Not At All Concerned With Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Situation

Dec 14
Here's Why We're Not At All Concerned With Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Situation

Shareholder Returns

NTLAUS BiotechsUS Market
7D-8.2%2.7%1.4%
1Y-58.3%-10.3%-16.1%

Return vs Industry: NTLA underperformed the US Biotechs industry which returned -10.3% over the past year.

Return vs Market: NTLA underperformed the US Market which returned -16.1% over the past year.

Price Volatility

Is NTLA's price volatile compared to industry and market?
NTLA volatility
NTLA Average Weekly Movement9.0%
Biotechs Industry Average Movement11.2%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: NTLA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: NTLA's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2014485John Leonardhttps://www.intelliatx.com

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders.

Intellia Therapeutics, Inc. Fundamentals Summary

How do Intellia Therapeutics's earnings and revenue compare to its market cap?
NTLA fundamental statistics
Market CapUS$3.60b
Earnings (TTM)-US$442.02m
Revenue (TTM)US$51.40m

70.1x

P/S Ratio

-8.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NTLA income statement (TTM)
RevenueUS$51.40m
Cost of RevenueUS$381.11m
Gross Profit-US$329.70m
Other ExpensesUS$112.31m
Earnings-US$442.02m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-5.62
Gross Margin-641.42%
Net Profit Margin-859.92%
Debt/Equity Ratio0%

How did NTLA perform over the long term?

See historical performance and comparison